SCHEMBL24619719

SCHEMBL24619719

CNC(=O)c1ccc(-c2cn3c(n2)sc2cc(C(=O)NCCOC)ccc23)cc1

nearest known ligand 0.68

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.68
▸ THRB P10828 2/20 0.65
▸ TP53 P04637 6/20 0.63
▸ MAPT P10636 4/20 0.61
▸ RXFP1 Q9HBX9 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24619961 0.94 TP53 (0.66) LMNATHRBTP53MAPT
SCHEMBL24619443 0.92 LMNA (0.65) LMNATHRBTP53MAPTRXFP1
SCHEMBL24741290 0.89 LMNA (0.67) LMNATHRBTP53MAPTRXFP1
SCHEMBL24619803 0.89 LMNA (0.68) LMNATHRBTP53MAPT
SCHEMBL24619462 0.88 LMNA (0.58) LMNATHRBTP53MAPTRXFP1
SCHEMBL24740826 0.87 MAPT (0.82) LMNATHRBTP53MAPT
SCHEMBL30086097 0.87 MAPT (0.82) LMNATHRBTP53MAPT
SCHEMBL24619417 0.86 LMNA (0.60) LMNATHRBTP53MAPTRXFP1
SCHEMBL24741269 0.86 LMNA (0.68) LMNATHRBTP53MAPT
SCHEMBL24619768 0.86 LMNA (0.65) LMNATHRBTP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404283-B2 c-MYC mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-09-02 — — US disclosed
US-20250129100-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-24 — — US disclosed
WO-2024010762-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2024-01-11 — — WO disclosed
EP-4274569-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2023-11-15 — — EP disclosed
CN-116635028-A Modulators of c-MYC mRNA translation and their use in the treatment of cancer 艾尼莫生物科技公司 2023-08-22 — — CN disclosed
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-11-24 — — US disclosed
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-11-24 — — US disclosed
WO-2022150316-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-07-14 — — WO disclosed
WO-2022150316-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 LMNA 1484/4885THRB 2134/4885TP53 96/4885
US-20250129100-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 LMNA 1484/4885THRB 2134/4885TP53 96/4885
US-12404283-B2 c-MYC mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 LMNA 1484/4885THRB 2134/4885TP53 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback